Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olga Caramelo, Cristina Silva, Francisco Caramelo, et al.
Hereditary Cancer in Clinical Practice (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer
Ke‐Da Yu, Fu-Gui Ye, Min He, et al.
JAMA Oncology (2020) Vol. 6, Iss. 9, pp. 1390-1390
Open Access | Times Cited: 158
Vorinostat (SAHA) and Breast Cancer: An Overview
Anna Wawruszak, Lidia Borkiewicz, Estera Okoń, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4700-4700
Open Access | Times Cited: 73
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
Giovanna Garufi, Antonella Palazzo, Ida Paris, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 6, pp. 687-699
Closed Access | Times Cited: 56
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Rita Ribeiro, Maria João Carvalho, João Gonçalves, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 35
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Luca Arecco, Marco Bruzzone, R. Bas, et al.
Annals of Oncology (2024) Vol. 35, Iss. 9, pp. 792-804
Open Access | Times Cited: 6
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
Nusayba A. Bagegni, Tao Yu, Foluso O. Ademuyiwa
PLoS ONE (2019) Vol. 14, Iss. 9, pp. e0222358-e0222358
Open Access | Times Cited: 44
Update on systemic treatment in early triple negative breast cancer
M. Nunez Abad, Sílvia Calabuig-Fariñas, M. Lobo de Mena, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 34
Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
Yue Chai, Yujie Chen, Di Zhang, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 323-323
Open Access | Times Cited: 26
Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
Akiyo Yoshimura, Issei Imoto, Hiroji Iwata
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7481-7481
Open Access | Times Cited: 26
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
Loïck Galland, Nicolas Roussot, Isabelle Desmoulins, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1299-1299
Open Access | Times Cited: 14
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
Yuan Yuan, Jin Sun Lee, Susan E. Yost, et al.
The Oncologist (2020) Vol. 26, Iss. 3, pp. e382-e393
Open Access | Times Cited: 33
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, et al.
Medicines (2020) Vol. 7, Iss. 9, pp. 54-54
Open Access | Times Cited: 28
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
Francesco Pavese, Ettore Capoluongo, Margherita Muratore, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4571-4571
Open Access | Times Cited: 17
Two-Photon Photodynamic Therapy Targeting Cancers with Low Carboxylesterase 2 Activity Guided by Ratiometric Fluorescence
Karishma Kailass, Oleg Sadovski, Warren R. Zipfel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8855-8868
Closed Access | Times Cited: 16
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence
Miloš Holánek, Iveta Selingerová, O Bílek, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1586-1586
Open Access | Times Cited: 23
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM)
Maria Vittoria Dieci, Lucia Del Mastro, Michela Cinquini, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1137-1137
Open Access | Times Cited: 23
Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
Changjun Wang, Ying Xu, Yan Lin, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 21
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials
Lei Bian, Ping Yu, Jiahuai Wen, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 17
Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity—An Isobolographic Analysis
Anna Wawruszak, Jarogniew J. Łuszczki, Joanna Kałafut, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 15, pp. 3663-3663
Open Access | Times Cited: 18
Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
Olga Caramelo, Cristina Silva, Francisco Caramelo, et al.
Hereditary Cancer in Clinical Practice (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 10
BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer
Amal Tazzite, H. Jouhadi, Abdellatif Benider, et al.
Current Drug Targets (2020) Vol. 21, Iss. 10, pp. 962-973
Closed Access | Times Cited: 13
Pathological complete response following cisplatin or carboplatin‑based neoadjuvant chemotherapy for triple‑negative breast cancer: A systematic review and meta‑analysis
Radu Vidra, Adina Nemeș, Andreea Vidrean, et al.
Experimental and Therapeutic Medicine (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Mass Spectrometry-Based Omics for the Characterization of Triple-Negative Breast Cancer Bio-Signature
Ioana-Ecaterina Pralea, Radu-Cristian Moldovan, Adrian Bogdan Țigu, et al.
Journal of Personalized Medicine (2020) Vol. 10, Iss. 4, pp. 277-277
Open Access | Times Cited: 12
Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
Wanyi Sun, Yun Wu, Fei Ma, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1588-1588
Open Access | Times Cited: 4
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
Hesham Elghazaly, Hope S. Rugo, Hamdy A. Azim, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2262-2262
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top